Dr. Reddy’s Voluntarily Recalls Five Lots of Ranitidine - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Dr. Reddy’s Voluntarily Recalls Five Lots of Ranitidine

The Indian pharmaceutical company Dr. Reddy’s Laboratories has initiated a voluntary recall of five lots of ranitidine hydrochloride tablets (150 mg, over-the-counter [OTC]) due to microbial contamination. The Class II recall was posted on FDA’s weekly enforcement report for Aug. 21, 2013 and initiated on Aug. 2, 2013.  Ranitidine is used to treat gastroesophageal reflux disease.

The recall, which is nationwide in the United States, was due to microbial contamination of nonsterile products. A lot of raw material used in the manufacture of ranitidine was positive for Pseudomonas sp.

The ranitidine hydrochloride tablets, USP 150 mg, OTC, were distributed as Equate brand Maximum Strength Acid Reducer (65-count bottle), Equaline brand Maximum Strength Heartburn Relief, and Wal-Zan brand 150, Maximum Strength (24- count bottle) and distributed respectively by Wal-Mart Stores, Supervalu, and Walgreen Co.

The affected lots were: 5055822, expiration date 03/13; 5056317, expiration date 03/15; 5056507, expiration date 04/15; 7956571C, expiration date 4/15; and 7956572A, expiration date 04/15.

Source: FDA


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here